Tuesday, January 22, 2019 11:11:28 AM
Precision Therapeutics Has Groundbreaking Approach to Personalized Cancer Treatment, Reports CEOCFO Magazine
ACCESSWIREJanuary 22, 2019
Precision Therapeutics is offering ''true personalized oncology,'' CEO Dr. Carl Schwartz tells CEOCFO Magazine, thanks to the company's unique database of tumors, artificial intelligence technology, and method for growing human cancer cells outside the body
BOCA RATON, FL / ACCESSWIRE / January 22, 2019 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with Dr. Carl Schwartz, President, CEO and Director of Precision Therapeutics Inc (AIPT).
Precision Therapeutics is bringing ''true personalized oncology,'' Dr. Schwartz explained to CEOCFO's Bud Wayne. Moreover, ''the same program is also invaluable to Big Pharma in the development of new drugs,'' Dr. Schwartz added.
The company's groundbreaking approach to personalized cancer treatment has three key elements. First, its wholly owned subsidiary TumorGenesis has pioneered the ability to grow human cancer cells outside the body, as COO Richard Gabriel described in a recent interview on CEOLIVE.TV. That makes it possible to extract cells from patients, grow them, and then ''functionally test the tumor from the patient by exposing it to different drugs,'' Dr. Schwartz explained. ''This is unique in the industry.''
Second, the company's Helomics subsidiary has amassed a huge data base of more than 150,000 tumors, including the genetics of each tumor. And third, Helomics has developed artificial intelligence technology, called the D-CHIP (Dynamic Clinical Health Insights Platform), that allows all the information from both a patient's own tumor and from similar cancers in the database (including how they respond to different drugs) to be quickly analyzed to find the best treatment for that patient. ''We are applying artificial intelligence to cancer one mutation at a time,'' said Dr. Schwartz. ''It's like having the experience of thousands of oncologists at your fingertips to choose the right drugs for patients.''
Precision Therapeutics already has begun selling kits to identify and extract cancer cells from patients, said Dr. Schwartz. It's also working to sign up pharmaceutical industry clients who can use the unique approach to discover and develop new and better cancer treatments. The potential impact will be huge, Dr. Schwartz said: ''We are focused on using this technology to help patients.''
Contact:
Bud Wayne
Editorial Executive
CEOCFO Magazine
570-851-1745
budwayne@ceocfomagazine.com
SOURCE: CEOCFO Magazine
Recent POAI News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/26/2024 04:15:15 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/15/2024 09:16:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:01:03 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:00:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 12:00:20 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/21/2024 07:39:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:01:08 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:00:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 10:00:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:00:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/07/2023 01:54:30 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/05/2023 09:15:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 10:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:06:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:06:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:05:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:03:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:03:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 10:25:18 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM